Firefly Neuroscience vs SOPHiA GENETICS
SOPHiA GENETICS reported revenue of $77 million in fiscal 2025, 70.3 times Firefly Neuroscience's $1 million in fiscal 2025. Firefly Neuroscience's revenue grew 957.4% in its latest year, and SOPHiA GENETICS's grew 18.6%. Firefly Neuroscience had an operating margin of -775.5%, against -91.8% at SOPHiA GENETICS.
Side by side
| Firefly Neuroscience | SOPHiA GENETICS | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1M | $77M |
| Revenue growth | 957.4% | 18.6% |
| Revenue growth a year, last 5 years | −39.8% | 22.2% |
| Gross margin | 56.5% | 67.4% |
| Operating margin | −775.5% | −91.8% |
| Net margin | −1,741.0% | −102.2% |
| Free cash flow | — | −$36M |
| Free cash flow margin | — | −47.2% |
| Return on capital | −411.7% | −207.1% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 90.1% | 2.2% |
| Last close | $0.80 | $6.68 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | bought $99,000, sold $4.2 million |
| Piotroski F-score | 4 of 9 | 2 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Firefly NeuroscienceSOPHiA GENETICS
Operating margin
Percent of revenue
Firefly NeuroscienceSOPHiA GENETICS
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Firefly NeuroscienceSOPHiA GENETICS
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Firefly Neuroscience and SOPHiA GENETICS pages.